Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

The stock's fall snapped a two-day winning streak.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report released on Thursday. Several other brokerages also ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...